Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
01/13/2017 01/16/2017 01/17/2017 01/18/2017 01/19/2017 Date
239(c) 235.6(c) 234.7(c) 235.6(c) 233 Last
1 489 418 1 311 955 1 550 278 1 751 036 1 623 113 Volume
+1.31% -1.42% -0.38% +0.38% -1.10% Change
More quotes
Financials ( CHF)
Sales 2016 51 095 M
EBIT 2016 17 589 M
Net income 2016 11 243 M
Debt 2016 11 033 M
Yield 2016 3,63%
Sales 2017 53 669 M
EBIT 2017 18 758 M
Net income 2017 12 374 M
Debt 2017 6 149 M
Yield 2017 3,85%
P/E ratio 2016 18,28
P/E ratio 2017 16,44
EV / Sales2016 4,22x
EV / Sales2017 3,93x
Capitalization 204 725 M
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the following segments: Diagnostics and Pharmaceuticals.The pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The... 
Sector
Pharmaceuticals
Calendar
02/01 | 07:00amEarnings Release
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
10:19p FOUNDATION MEDICINE : Announces Executive Leadership Transition
11:15a GSK grabs Astra executive to replace pharma head
09:18a EISAI : acquires manufacturing rights for API from Roche to treat insomnia
12:31a ROCHE : Extended FDA Review for Lilly/Incyte's Olumiant (baricitinib) in Rheumat..
01/18 Global Influenza Market Has Been Accelerated USD 6.87 Billion in 2020
01/18 ROCHE : FDA Grants Genentech's Cancer Immunotherapy Tecentriq (Atezolizumab) Pri..
01/18 Drugmakers in Davos shift focus to chronic diseases of poor
01/17 ROCHE : Multiplex System Addresses IHC Needs
01/16 Global Lycopene Market 2017 - DSM, BASF, NIPPON, Kagome, Bayer, KIRIN, Roche ..
01/13 ROCHE : Johnson & Johnson and Alstrom Syndrome UK Address Hot Topic of Paediatri..
More news
Sector news : Pharmaceuticals - NEC
10:13pDJRival to EpiPen Allergy Treatment to Return to Market--Update
09:03pDJRival to EpiPen Allergy Treatment to Return to Market
04:33p Davos CEOs 'go local' on supply chain in Trump era
11:15a GSK grabs Astra executive to replace pharma head
10:40aDJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave -- Upd..
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on ROCHE HOLDING LTD. 
2016An opportunity over the medium term?
2016A medium term support level to take advantage of
More Strategies
Latest Tweets
07:33pRoche Release: Breakthrough Development For Americans With Suspected Heart At.. 
06:35pBRIEF-Roche Holding AG says Troponin T test cleared by FDA  
05:51p(BN) Roche's Franz: No Talks With Novartis on Stake Sale  
03:20pRoche's Franz: No talks with Novartis on stake sale  
09:20aWatch Roche Chariman Franz speak with @BloombergTV at 9:30 a.m. Davos time fr.. 
More tweets
Qtime:116
News from SeekingAlpha
01/18 Astra's Mystic Mystery And Other Surprises In Store
01/18 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2016 Update
01/17 Even A $100M Series A Can't Save The Medtech Venture Climate
01/17 AnaptysBio Sets Terms For $60 Million IPO
01/13 BIOTECHS : What The 'Trump Dump' And CVS's EpiPen Move May Mean
Advertisement
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 282  CHF
Spread / Average Target 19%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.1.29%203 230
JOHNSON & JOHNSON-0.44%312 045
PFIZER INC.-1.39%194 369
NOVARTIS AG-3.71%189 507
MERCK & CO., INC.3.91%168 654
SANOFI-0.52%105 178
More Results